Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis

TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells

(2014) Susann Voigt et al.   BMC CANCER

Distinct roles of RIP1–RIP3 hetero- and RIP3–RIP3 homo-interaction in mediating necroptosis

(2014) X-N Wu et al.   CELL DEATH AND DIFFERENTIATION

Getting TRAIL back on track for cancer therapy

(2014) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

Mixed Lineage Kinase Domain-like Protein MLKL Causes Necrotic Membrane Disruption upon Phosphorylation by RIP3

(2014) Huayi Wang et al.   MOLECULAR CELL

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

(2013) J. Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms

(2013) Lenka Beranova et al.   APOPTOSIS

Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma

(2013) Lauren E. Colbert et al.   CANCER

The proteases HtrA2/Omi and UCH-L1 regulate TNF-induced necroptosis

(2013) Justyna Sosna et al.   Cell Communication and Signaling

TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct routes to programmed necrotic cell death

(2013) Justyna Sosna et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval

(2013) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib

(2013) Jorge E. Cortes et al.   Clinical Lymphoma Myeloma & Leukemia

Necrosis-dependent and independent signaling of the RIP kinases in inflammation

(2013) Kenta Moriwaki et al.   CYTOKINE & GROWTH FACTOR REVIEWS

The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism

(2013) James M. Murphy et al.   IMMUNITY

Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways

(2013) M van Dijk et al.   Cell Death & Disease

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

(2012) J. Cortes et al.   BLOOD

Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase

(2012) Liming Sun et al.   CELL

TRAIL: A Sword for Killing Tumors

(2012) S. Wang   CURRENT MEDICINAL CHEMISTRY

TRAIL Signaling and Synergy Mechanisms Used in TRAIL-Based Combination Therapies

(2012) C. T. Hellwig et al.   MOLECULAR CANCER THERAPEUTICS

Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis

(2012) J. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tamoxifen enhances therapeutic effects of gemcitabine on cholangiocarcinoma tumorigenesis

(2011) Gu Jing et al.   LABORATORY INVESTIGATION

Molecular mechanisms of necroptosis: an ordered cellular explosion

(2010) Peter Vandenabeele et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features

(2009) T Vanden Berghe et al.   CELL DEATH AND DIFFERENTIATION

TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies

(2009) Peter A. Holoch et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Identification of RIP1 kinase as a specific cellular target of necrostatins

(2008) Alexei Degterev et al.   Nature Chemical Biology

Expansion and evolution of cell death programmes

(2008) Alexei Degterev et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY